Lantheus, RefleXion to collaborate on prostate cancer treatment

2016 10 04 11 38 34 158 Prostate 400

Lantheus Medical Imaging parent Lantheus Holdings and radiation therapy equipment developer RefleXion Medical have signed a development and marketing partnership to evaluate the use of Lantheus' prostate-specific membrane antigen (PSMA)-targeted PET agent piflufolastat F-18 with RefleXion's X1 biology-guided radiotherapy system.

RefleXion X1 combines PET technology with radiation therapy delivery, allowing for real-time treatment guidance using tumor biology, Lantheus said.

The agreement will be managed by a joint steering committee and will be focused on securing U.S. regulatory approval to treat patients with biology-guided radiotherapy using piflufolastat F-18.

Page 1 of 597
Next Page